ArticleCell biology and toxicology2026
METTL7B-stabilized lncRNA-MIR22HG to drive p53-mediated neuronal apoptosis via the ubiquitinating JARID2 in cerebral ischemia/reperfusion injury.
Article in Cell biology and toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Ischemic stroke (IS) constitutes a leading driver of mortality and morbidity worldwide, with neuronal apoptosis representing a key pathological process. Accordingly, our objective was to delve into the implications of a novel signaling axis of the m6A methyltransferase METTL7B, lncRNA-MIR22HG, and JARID2 in driving neuronal apoptosis throughout cerebral ischemia/reperfusion (I/R) injury (CIRI). Mice subjected to middle cerebral artery occlusion/reperfusion (MCAO/R) and N2a cells exposed to oxygen-glucose deprivation/reoxygenation (OGD/R) were, respectively, established as in vivo and in vitro I/R models. METTL7B was markedly up-regulated after I/R and enhanced the m6A methylation and stability of lncRNA-MIR22HG, significantly prolonging its transcript half-life and amplifying its biological effects on neuronal fate. Stabilized lncRNA-MIR22HG suppressed the ubiquitin-mediated degradation of JARID2, thereby increasing JARID2 abundance and activity. Elevated JARID2 promoted the assembly of the p53/p300/MDM2 transcriptional complex, which in turn up-regulated the levels of pro-apoptotic genes, ultimately exacerbating neuronal apoptosis alongside ischemic brain injury. Functionally, METTL7B overexpression aggravated neurological deficits, infarct volume, and neuronal apoptosis in vivo, whereas METTL7B knockdown alleviated ischemic damage and conferred robust neuroprotection. Collectively, these findings define a novel METTL7B/lncRNA-MIR22HG/JARID2 signaling axis that integrates RNA methylation, lncRNA stabilization, proteostasis, and transcriptional activation of apoptosis, and highlight METTL7B as a potential novel target for therapeutic strategies aimed at preventing and treating ischemic stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.